These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 24195728)
21. Medical therapy of advanced malignant epithelial tumours of the ovary. Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983 [TBL] [Abstract][Full Text] [Related]
22. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. Galsky MD; Moshier E; Krege S; Lin CC; Hahn N; Ecke T; Sonpavde G; Godbold J; Oh WK; Bamias A Cancer; 2013 Aug; 119(16):3012-9. PubMed ID: 23720216 [TBL] [Abstract][Full Text] [Related]
23. Emerging drugs for urothelial (bladder) cancer. Cumberbatch K; He T; Thorogood Z; Gartrell BA Expert Opin Emerg Drugs; 2017 Jun; 22(2):149-164. PubMed ID: 28556678 [TBL] [Abstract][Full Text] [Related]
24. Current treatment of metastatic bladder cancer and future directions. Lei AQ; Cheng L; Pan CX Expert Rev Anticancer Ther; 2011 Dec; 11(12):1851-62. PubMed ID: 22117153 [TBL] [Abstract][Full Text] [Related]
25. The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). Audenet F; Yates DR; Cussenot O; Rouprêt M Urol Oncol; 2013 May; 31(4):407-13. PubMed ID: 20884249 [TBL] [Abstract][Full Text] [Related]
26. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy. George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577 [TBL] [Abstract][Full Text] [Related]
27. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). Boulikas T; Vougiouka M Oncol Rep; 2004 Mar; 11(3):559-95. PubMed ID: 14767508 [TBL] [Abstract][Full Text] [Related]
28. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group. Vaughn DJ; Manola J; Dreicer R; See W; Levitt R; Wilding G Cancer; 2002 Sep; 95(5):1022-7. PubMed ID: 12209686 [TBL] [Abstract][Full Text] [Related]
29. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control. Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605 [TBL] [Abstract][Full Text] [Related]
30. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684 [TBL] [Abstract][Full Text] [Related]
31. Can patient selection for bladder preservation be based on response to chemotherapy? Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521 [TBL] [Abstract][Full Text] [Related]
32. Evaluating the association of multiple single nucleotide polymorphisms with response to gemcitabine and platinum combination chemotherapy in urothelial carcinoma of the bladder . Alanee SR; Shah S; Zabor EC; Vijai J; Ostrovnaya I; Garcia-Grossman IR; Pendse DV; Littman J; Regazzi AM; Offit K; Bajorin DF Int J Clin Pharmacol Ther; 2017 Mar; 55(3):203-209. PubMed ID: 28177276 [TBL] [Abstract][Full Text] [Related]
33. Muscle-invasive urothelial carcinoma of the bladder: neoadjuvant chemotherapy enables organ-preserving therapy in carefully selected patients. Heidenreich A Eur Urol; 2008 Jul; 54(1):21-3. PubMed ID: 18262722 [No Abstract] [Full Text] [Related]
34. Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand? Buti S; Ciccarese C; Zanoni D; Santoni M; Modena A; Maines F; Gilli A; Bria E; Brunelli M; Rimanti A; Cascinu S; Ardizzoni A; Tortora G; Massari F Future Oncol; 2015; 11(1):107-19. PubMed ID: 25572786 [TBL] [Abstract][Full Text] [Related]
35. Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise. Zachos I; Konstantinopoulos PA; Tzortzis V; Gravas S; Karatzas A; Karamouzis MV; Melekos M; Papavassiliou AG Expert Opin Investig Drugs; 2010 Jul; 19(7):875-87. PubMed ID: 20528482 [TBL] [Abstract][Full Text] [Related]
36. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma. Siu LL; Banerjee D; Khurana RJ; Pan X; Pflueger R; Tannock IF; Moore MJ Clin Cancer Res; 1998 Mar; 4(3):559-65. PubMed ID: 9533522 [TBL] [Abstract][Full Text] [Related]
37. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Sonpavde G; Sternberg CN; Rosenberg JE; Hahn NM; Galsky MD; Vogelzang NJ Lancet Oncol; 2010 Sep; 11(9):861-70. PubMed ID: 20537950 [TBL] [Abstract][Full Text] [Related]